These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35382764)

  • 1. Migraine, interferon β1a and siponimod immunomodulator therapies.
    Dahaba AA; Bornemann-Cimenti H
    BMC Anesthesiol; 2022 Apr; 22(1):95. PubMed ID: 35382764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
    Schur N; Gudala K; Vudumula U; Vadapalle S; Bhadhuri A; Casanova A; Adlard N; Schwenkglenks M
    Pharmacoeconomics; 2021 May; 39(5):563-577. PubMed ID: 33791945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
    Boyko AN; Boyko OV; Bakhtiyarova KZ; Gusev EI; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Poverennova IY; Siverceva SA; Totolyan NA; Shchur SG; Fedulov AS; Khabirov FA; Bolsun DD; Zinkina-Orikhan AV; Linkova YN; Chernovskaya TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):62-71. PubMed ID: 35175704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Saccà F; Russo CV; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2018 Jan; 19():50-54. PubMed ID: 29128737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
    Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
    CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Migraines linked to interferon-beta treatment of multiple sclerosis.
    Khromov A; Segal M; Nissinoff J; Fast A
    Am J Phys Med Rehabil; 2005 Aug; 84(8):644-7. PubMed ID: 16034235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance.
    Sabidó M; Venkatesh S; Hayward B; Aldridge J; Gillett A
    Adv Ther; 2018 Nov; 35(11):2041-2053. PubMed ID: 30255416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.
    Li DK; Paty DW
    Ann Neurol; 1999 Aug; 46(2):197-206. PubMed ID: 10443885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis.
    Villani V; Prosperini L; De Giglio L; Pozzilli C; Salvetti M; Sette G
    Headache; 2012; 52(7):1130-5. PubMed ID: 22486199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis.
    Mazdeh M; Mobaien AR
    Iran J Neurol; 2012; 11(2):70-3. PubMed ID: 24250865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.
    De Stefano N; Curtin F; Stubinski B; Blevins G; Drulovic J; Issard D; Shotekov P; Gasperini C;
    Mult Scler; 2010 Jul; 16(7):888-92. PubMed ID: 20200197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.